Core One Labs Inc. (OTCQB:CLABF) (CSE:COOL)(Frankfurt:LD6) (WKN:A3CSSU) announced that its wholly-owned subsidiary, Awakened Biosciences Inc. has successfully completed the first synthetic production of psilocin at the GMP manufacturing facility of its recently acquired GMP Drug Inc.
"Awakened's successful first synthetic production of psilocin at the GMP Drug Inc. facilities is a major accomplishment for Core One, and it lays the groundwork for the large-scale production of psychedelic compounds at a GMP certified facility. As Core One looks to become a major supplier of psychedelic compounds, it is important that we demonstrate the company's ability to execute at each stage of our strategic process. This achievement brings us one step closer to our long-term goal of supplying the medical community with affordable, API grade, psychedelic compounds," stated Joel Shacker CEO of the company.
The successful synthesis of psilocin advances previous work conducted by Awakened, where its team of scientist witnessed success in the ability to produce a precursor that can be efficiently converted into psilocin, with further conversion into commercially viable psilocybin. The confirmation of Awakened's synthetic production methods is also extremely important for the future developments of the company, as it lays the path upon which additional research can be conducted. As such, Awakened will look to replicate methods used in the successful synthetic production of psilocin and subsequent conversion to psilocybin, for future production of dimethyltryptamine and its intermediates, and other psychedelic prodrugs and compounds.
The research and resulting production have been led by CEO of Awakened, Dr. Tony Durst, who is also an emeritus professor at the University of Ottawa, and a renowned specialist in medicinal and natural product chemistry. Dr. Durst's previous successes are many and include the awarding of 14 successful patents, of which he was co-inventor.
Photo by Louis Reed on Unsplash
Related News
Across The Globe: Psychedelic Trials To Treat Late-Stage Cancer, Alzheimer's Begin